Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADC Therapeutics SARL

www.adctherapeutics.com

Latest From ADC Therapeutics SARL

Finance Watch: Ayala Launches First Biopharma IPO In May

The cancer drug developer raised $55m. Also, Lyra raised $56m in the last of four biopharma IPOs in April, Biogen sold $3bn worth of debt, Oberland raised a $1.05bn fund and Praxis launched with more than $100m. 

Financing Innovation

Why BerGenBio’s Bemcentinib Will Kick-Off UK’s COVID-19 ACCORD Program

There is strong scientific rationale from US and UK research to support evaluating the selective AXL kinase inhibitor bemcentinib in the UK’s early-stage clinical study program, ACCORD, a new initiative to find potential COVID-19 therapies.

Coronavirus COVID-19 Clinical Trials

Deal Watch: Genentech Sees Bicycle As Route To Novel Targeted Cancer Immunotherapies

Genentech pays $30m up front in a collaboration with Bicycle in a deal that could bring the UK biotech roughly $1.7bn in total. Also, deals involving Nimble, Seattle Genetics, Five Prime, Fresenius, Vifor, Yuhan, Imnewrun, Paratek, Almirall, MBD, AzothBio, Norgine, Faes, Aspen Pharmacare, Swixx.

Deals Business Strategies

European Biotechs Enter the IPO Big League

2019 has seen European biotech companies making waves in the US IPO space. Genmab’s listing was a blockbuster, but many more companies have proven their ability to go public on the NASDAQ.

Europe Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • ADC Therapeutics SARL
  • Senior Management
  • Chris Martin, PhD, CEO
    Michael Forer, EVP, CFO
    Patrick van Berkel, PhD, SVP, R&D
    Jay Feingold, MD, PhD, SVP, CMO & Head, Oncology
  • Contact Info
  • ADC Therapeutics SARL
    Phone: 21 653 02 00
    Route de la Corniche 3B
    Biopole
    Epalinges, 1066
    Switzerland
UsernamePublicRestriction

Register